Responder rates* at day 5–8 visit
| Analysis | Treatment group | % Responders | Relative odds† | p Value† |
|---|---|---|---|---|
| RAST = radio-allergosorbent test; ITT = intent to treat; PP = per protocol. *The percentage of subjects showing excellent or good response. †Ketotifen response compared with that of either placebo or levocabastine, respectively. p Values not corrected for multiple analyses. §Target population. | ||||
| Subject assessment (RAST positive ITT§) | Ketotifen (n = 109) | 49.5 | ||
| Placebo (n = 106) | 33.0 | 1.99 | 0.02 | |
| Levocabastine (n = 107) | 41.1 | 1.43 | 0.20 | |
| Investigator assessment (RAST positive ITT§) | Ketotifen (n = 109) | 53.2 | ||
| Placebo (n = 106) | 32.1 | 2.49 | 0.001 | |
| Levocabastine (n = 107) | 45.8 | 1.39 | 0.24 | |
| Subject assessment (ITT) | Ketotifen (n = 163) | 47.9 | ||
| Placebo (n = 165) | 39.4 | 1.41 | 0.13 | |
| Levocabastine (n = 166) | 38.6 | 1.46 | 0.09 | |
| Investigator assessment (ITT) | Ketotifen (n = 163) | 50.3 | ||
| Placebo (n = 165) | 38.2 | 1.66 | 0.02 | |
| Levocabastine (n = 166) | 41.0 | 1.45 | 0.09 | |
| Subject assessment (PP) | Ketotifen (n = 85) | 50.6 | ||
| Placebo (n = 78) | 35.9 | |||
| Levocabastine (n = 75) | 41.3 | 1.83 | 0.06 | |
| Investigator assessment (PP) | Ketotifen (n = 85) | 56.5 | 1.48 | 0.30 |
| Placebo (n = 78) | 34.6 | 2.51 | 0.005 | |
| Levocabastine (n = 75) | 46.7 | 1.58 | 0.16 | |